(Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine is under clinical development by Micron Biomedical and currently in Phase II for Measles. According to GlobalData, Phase II drugs for Measles have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine overview
Vaccine candidate is under development for the prevention of measles and rubella. It is a live attenuated vaccine administered by transdermal route. The therapeutic candidate is developed based on microneedle patch technology.
Micron Biomedical overview
Micron Biomedical (Micron) is a biopharmaceutical company that is engaged in research and development of pharmaceutical products by using microneedle patch technology. The company is headquartered in Atlanta, Georgia, the US.
For a complete picture of (Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
